Authors:
Luis Felipe, Reyes, Srinivas, Murthy, Esteban, Garcia-Gallo, Mike, Irvine, Laura, Merson, Ignacio, Martin-Loeches, Jordi, Rello, Fabio S, Taccone, Robert A, Fowler, Annemarie B, Docherty, Christiana, Kartsonaki, Irene, Aragao, Peter W, Barrett, Abiga (...)
Luis Felipe, Reyes, Srinivas, Murthy, Esteban, Garcia-Gallo, Mike, Irvine, Laura, Merson, Ignacio, Martin-Loeches, Jordi, Rello, Fabio S, Taccone, Robert A, Fowler, Annemarie B, Docherty, Christiana, Kartsonaki, Irene, Aragao, Peter W, Barrett, Abigail, Beane, Aidan, Burrell, Matthew Pellan, Cheng, Michael D, Christian, Jose Pedro, Cidade, Barbara Wanjiru, Citarella, Christl A, Donnelly, Susana M, Fernandes, Craig, French, Rashan, Haniffa, Ewen M, Harrison, Antonia Ying Wai, Ho, Mark, Joseph, Irfan, Khan, Michelle E, Kho, Anders Benjamin, Kildal, Demetrios, Kutsogiannis, François, Lamontagne, Todd C, Lee, Gianluigi Li, Bassi, Jose Wagner, Lopez Revilla, Catherine, Marquis, Jonathan, Millar, Raul, Neto, Alistair, Nichol, Rachael, Parke, Rui, Pereira, Sergio, Poli, Pedro, Povoa, Kollengode, Ramanathan, Oleksa, Rewa, Jordi, Riera, Sally, Shrapnel, Maria Joao, Silva, Andrew, Udy, Timothy, Uyeki, Steve A, Webb, Evert-Jan, Wils, Amanda, Rojek, Piero L, Olliaro
(Read More)
Abstract:
Respiratory infections and tuberculosis Infecciones respiratorias y tuberculosis Infeccions respiratòries i tuberculosi Due to the large number of patients with severe coronavirus disease 2019 (COVID-19), many were treated outside the traditional walls of the intensive care unit (ICU), and in many cases, by personnel who were not trained in critical care. The clinical characteristics and the relative impact of caring for severe COVID-19 patients outside the ICU is unknown. This was a multinational, multicentre, prospective cohort study embedde (...)
Respiratory infections and tuberculosis Infecciones respiratorias y tuberculosis Infeccions respiratòries i tuberculosi Due to the large number of patients with severe coronavirus disease 2019 (COVID-19), many were treated outside the traditional walls of the intensive care unit (ICU), and in many cases, by personnel who were not trained in critical care. The clinical characteristics and the relative impact of caring for severe COVID-19 patients outside the ICU is unknown. This was a multinational, multicentre, prospective cohort study embedded in the International Severe Acute Respiratory and Emerging Infection Consortium World Health Organization COVID-19 platform. Severe COVID-19 patients were identified as those admitted to an ICU and/or those treated with one of the following treatments: invasive or noninvasive mechanical ventilation, high-flow nasal cannula, inotropes or vasopressors. A logistic generalised additive model was used to compare clinical outcomes among patients admitted or not to the ICU. A total of 40 440 patients from 43 countries and six continents were included in this analysis. Severe COVID-19 patients were frequently male (62.9%), older adults (median (interquartile range (IQR), 67 (55–78) years), and with at least one comorbidity (63.2%). The overall median (IQR) length of hospital stay was 10 (5–19) days and was longer in patients admitted to an ICU than in those who were cared for outside the ICU (12 (6–23) days versus 8 (4–15) days, p<0.0001). The 28-day fatality ratio was lower in ICU-admitted patients (30.7% (5797 out of 18 831) versus 39.0% (7532 out of 19 295), p<0.0001). Patients admitted to an ICU had a significantly lower probability of death than those who were not (adjusted OR 0.70, 95% CI 0.65–0.75; p<0.0001). Patients with severe COVID-19 admitted to an ICU had significantly lower 28-day fatality ratio than those cared for outside an ICU. This work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome (215091/Z/18/Z), the Bill and Melinda Gates Foundation (OPP1209135), Canadian Institutes of Health Research Coronavirus Rapid Research Funding Opportunity OV2170359, grants from Rapid European COVID-19 Emergency Response Research (Horizon 2020 project 101003589), the European Clinical Research Alliance on Infectious Diseases (965313), The Imperial National Institute for Health Research (NIHR) Biomedical Research Centre, and The Cambridge NIHR Biomedical Research Centre; and endorsed by the Irish Critical Care Clinical Trials Group, co-ordinated in Ireland by the Irish Critical Care Clinical Trials Network at University College Dublin and funded by the Health Research Board of Ireland (CTN-2014-12). Data and Material provision was supported by grants from: the NIHR (award CO-CIN-01), the Medical Research Council (grant MC_PC_19059), the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE) (award 200907), Wellcome Trust (Turtle, Lance-fellowship 205228/Z/16/Z), NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award 200927), Liverpool Experimental Cancer Medicine Centre (grant C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (award IS-BRC-1215-20013), and NIHR Clinical Research Network providing infrastructure support. This work was by Research Council of Norway grant number 312780, and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner.
(Read More)